Y-mAbs Therapeutics Inc
(NASDAQ:YMAB)
$6.32
0[0.00%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$6.32
0[0.00%]
After-Hours
Open-Close-
Vol / Avg.2.000 / 175.997KMkt Cap275.689M
Day Range- - -52 Wk Range2.700 - 10.950

Y-mAbs Therapeutics Stock (NASDAQ:YMAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$56.00

Lowest Price Target1

$5.00

Consensus Price Target1

$13.73

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
60220

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • JP Morgan
  • Morgan Stanley
  • Canaccord Genuity
  • Wedbush

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Y-mAbs Therapeutics

Upgrades (2)

Downgrades (8)

Initiations (1)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
11/15/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3274.05%HC Wainwright & Co.
Robert Burns
→ $11ReiteratesBuy → BuyGet Alert
08/22/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3210.76%JP Morgan
Tessa Romero
$8 → $7MaintainsUnderweightGet Alert
08/14/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32-20.89%Morgan Stanley
Michael Ulz
$7 → $5MaintainsUnderweightGet Alert
08/14/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3274.05%HC Wainwright & Co.
Robert Burns
→ $11ReiteratesBuy → BuyGet Alert
07/25/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32248.1%Canaccord Genuity
William Plovanic
$21 → $22MaintainsBuyGet Alert
12/15/2022YMABBuy Now
Y-mAbs Therapeutics
$6.32-5.06%B of A Securities
Alec Stranahan
$5 → $6MaintainsNeutralGet Alert
04/01/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32-5.06%B of A Securities
Alec Stranahan
→ $6MaintainsNeutralGet Alert
05/07/2021YMABBuy Now
Y-mAbs Therapeutics
$6.32786.08%B of A Securities
Geoff Meacham
→ $56UpgradeNeutral → BuyGet Alert
06/07/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32232.28%Canaccord Genuity
William Plovanic
→ $21ReiteratesBuy → BuyGet Alert
05/15/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3289.87%B of A Securities
Alec Stranahan
$6 → $12MaintainsNeutralGet Alert
05/10/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3210.76%Morgan Stanley
Michael Ulz
$4 → $7MaintainsUnderweightGet Alert
05/10/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32105.7%Wedbush
David Nierengarten
$5 → $13UpgradeNeutral → OutperformGet Alert
05/09/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32232.28%Canaccord Genuity
William Plovanic
$18 → $21MaintainsBuyGet Alert
04/04/2023YMABBuy Now
Y-mAbs Therapeutics
$6.3274.05%HC Wainwright & Co.
Robert Burns
$19 → $11MaintainsBuyGet Alert
04/03/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32Guggenheim
Etzer Darout
DowngradeBuy → NeutralGet Alert
03/31/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32184.81%Canaccord Genuity
William Maughan
$20 → $18MaintainsBuyGet Alert
01/30/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32105.7%BMO Capital
Etzer Darout
$12 → $13MaintainsOutperformGet Alert
01/27/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32Morgan Stanley
Michael Ulz
DowngradeEqual-Weight → UnderweightGet Alert
01/05/2023YMABBuy Now
Y-mAbs Therapeutics
$6.32Cowen & Co.
Joseph Thome
DowngradeOutperform → Market PerformGet Alert
Q

What is the target price for Y-mAbs Therapeutics (YMAB)?

A

The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $11.00 expecting YMAB to rise to within 12 months (a possible 74.05% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?

A

The latest analyst rating for Y-mAbs Therapeutics (NASDAQ: YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.

Q

Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?

A

While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a reiterated with a price target of $0.00 to $11.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $6.32, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.